Overall, these results validate the efficacy of CancerHubs predictions and establish TGOLN2 as a novel broad cancer hub with tumour suppressor-like properties and EFTUD2 as a novel MM hub with oncogenic properties. Here, TGOLN2 is linked to Miyoshi myopathy.